Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

235
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
235
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

836
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

165
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
165
Metabolic States of the Body: The Postabsorptive State01:18

Metabolic States of the Body: The Postabsorptive State

1.2K
The postabsorptive state usually starts about four hours after a meal and lasts until the next meal is eaten. During this time, the digestive system stops absorbing nutrients, and the body uses stored energy reserves to maintain stable blood glucose levels.
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
1.2K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

217
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
217
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

673
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
673

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Metabolomic signature of ultra-processed foods and cardiovascular morbidity and mortality.

Clinical nutrition (Edinburgh, Scotland)·2026
Same author

Prevalence of Pre-Clinical Obesity Among US Adults Receiving Medical and Surgical Obesity Treatment.

Obesity (Silver Spring, Md.)·2026
Same author

Distinct cell-type contributions and network topography of theta-nested gamma oscillations in the medial entorhinal cortex.

bioRxiv : the preprint server for biology·2026
Same author

Obesity Treatment Pathways and Implementation in Health Systems.

Obesity science & practice·2026
Same author

Obesity-Related Metabolites are Associated with Incident Coronary Heart Disease and Respond to Metabolic and Bariatric Surgery.

medRxiv : the preprint server for health sciences·2026
Same author

Association of physical activity with gut microbiome among low-income black American adults in the Southern Community Cohort Study.

Gut microbes reports·2026

Related Experiment Video

Updated: Jan 13, 2026

Roux-en-Y Gastric Bypass Operation in Rats
07:37

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

24.2K

Body Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists.

Zicheng Wang1, Lei Wang1, Xinmeng Zhang2

  • 1Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

JAMA Network Open
|January 9, 2026
PubMed
Summary

Bariatric surgery and GLP-1RAs (semaglutide, tirzepatide) significantly reduce fat mass and preserve fat-free mass. Both treatments improve body composition, with surgery showing greater fat mass reduction and better fat-free mass preservation.

More Related Videos

Sleeve Gastrectomy in Mice using Surgical Clips
05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

7.3K
Techniques of Sleeve Gastrectomy and Modified Roux-en-Y Gastric Bypass in Mice
10:05

Techniques of Sleeve Gastrectomy and Modified Roux-en-Y Gastric Bypass in Mice

Published on: March 20, 2017

12.6K

Related Experiment Videos

Last Updated: Jan 13, 2026

Roux-en-Y Gastric Bypass Operation in Rats
07:37

Roux-en-Y Gastric Bypass Operation in Rats

Published on: June 11, 2012

24.2K
Sleeve Gastrectomy in Mice using Surgical Clips
05:16

Sleeve Gastrectomy in Mice using Surgical Clips

Published on: November 14, 2020

7.3K
Techniques of Sleeve Gastrectomy and Modified Roux-en-Y Gastric Bypass in Mice
10:05

Techniques of Sleeve Gastrectomy and Modified Roux-en-Y Gastric Bypass in Mice

Published on: March 20, 2017

12.6K

Area of Science:

  • Metabolic and Bariatric Surgery
  • Pharmacology and Drug Discovery
  • Obesity Medicine

Background:

  • Evidence linking bariatric surgery and newer glucagon-like peptide-1 receptor agonists (GLP-1RAs) like semaglutide and tirzepatide to body composition changes is limited in clinical settings.
  • Understanding the impact of these interventions on fat-free mass (FFM), fat mass (FM), and their ratio is crucial for managing obesity and metabolic health.

Purpose of the Study:

  • To investigate the temporal changes in FFM, FM, and the FFM to FM ratio over 24 months following bariatric surgery or GLP-1RA treatment.
  • To compare the effects of bariatric surgery versus GLP-1RA therapy on body composition parameters.

Main Methods:

  • A retrospective cohort study utilizing electronic health records from Vanderbilt University Medical Center.
  • Included 1257 patients undergoing bariatric surgery and 1809 non-surgical patients treated with semaglutide or tirzepatide.
  • Analyzed bioelectrical impedance analysis data over 24 months, controlling for demographic and clinical factors.

Main Results:

  • Both bariatric surgery and GLP-1RA treatment led to significant fat mass reduction and moderate fat-free mass loss.
  • Bariatric surgery resulted in greater fat mass reduction (49.7% at 24 months) compared to GLP-1RAs (18.0% at 24 months).
  • Fat-free mass loss was also greater with surgery (11.7% at 24 months) versus GLP-1RAs (3.3% at 24 months), but the FFM to FM ratio improved in both groups, favoring surgery.

Conclusions:

  • Bariatric surgery and GLP-1RA treatments (semaglutide, tirzepatide) are associated with substantial fat loss and moderate fat-free mass loss.
  • Both interventions improve the FFM to FM ratio, indicating a favorable shift in body composition.
  • Findings support the use of these interventions for fat loss and provide insights for strategies to preserve fat-free mass.